CH529723A - Unsatd. amine(s), tranquillisers and vasodilators - Google Patents
Unsatd. amine(s), tranquillisers and vasodilatorsInfo
- Publication number
- CH529723A CH529723A CH1511271A CH1511271A CH529723A CH 529723 A CH529723 A CH 529723A CH 1511271 A CH1511271 A CH 1511271A CH 1511271 A CH1511271 A CH 1511271A CH 529723 A CH529723 A CH 529723A
- Authority
- CH
- Switzerland
- Prior art keywords
- radical
- dependent
- salts
- alk
- denotes
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title abstract 2
- 229940124549 vasodilator Drugs 0.000 title abstract 2
- 239000003071 vasodilator agent Substances 0.000 title abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 7
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- -1 alkylene radical Chemical class 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 150000003254 radicals Chemical class 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000001294 propane Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000005394 methallyl group Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- DITHIFQMPPCBCU-UHFFFAOYSA-N propa-1,2-diene Chemical compound [CH]=C=C DITHIFQMPPCBCU-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- KHACGQCFBNBHCV-UHFFFAOYSA-N 1-(propan-2-ylamino)-3-(4-prop-2-ynoxyphenoxy)propan-2-ol Chemical compound CC(C)NCC(O)COC1=CC=C(OCC#C)C=C1 KHACGQCFBNBHCV-UHFFFAOYSA-N 0.000 claims 1
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical compound C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 125000002947 alkylene group Chemical group 0.000 abstract description 2
- 150000001299 aldehydes Chemical class 0.000 abstract 2
- 239000007859 condensation product Substances 0.000 abstract 2
- 150000002430 hydrocarbons Chemical class 0.000 abstract 2
- 150000002576 ketones Chemical class 0.000 abstract 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000003700 epoxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 235000013849 propane Nutrition 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical compound C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 1
- LNSCNEJNLACZPA-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(2-methylphenyl)butanedioic acid Chemical compound CC1=CC=CC=C1C(O)(C(O)=O)C(O)(C(O)=O)C1=CC=CC=C1C LNSCNEJNLACZPA-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- QPVVYHVQHOCTAP-UHFFFAOYSA-N C1(CCCCC1)NS(O)(=O)=O.C(C)(C)NCC(COC1=CC=C(C=C1)OCC#C)O Chemical compound C1(CCCCC1)NS(O)(=O)=O.C(C)(C)NCC(COC1=CC=C(C=C1)OCC#C)O QPVVYHVQHOCTAP-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004848 alkoxyethyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical compound C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Unsatd. amines-tranquillisers, vasodilators. New cpds. of formula: R-alk-o-Ph-O-CH2-CH(OH)-CH2-NH-R1 (where "alk" is alkylene, R is unsatd. aliph. hydrocarbon, R1 is aliphatic hydrocarbon =15C opt. with heteroatoms inserted e.g. O, S, N and/or substd. by -OH, cyclo-aliphatic hydrocarbon =15C or an araliphatic hydrocarbon (opt. subst.) =15C; Ph is 1,4-phenylene (opt. subst.)) and their condensation products with aldehydes and ketones are prepared by reaction of R-alk-o-Ph-O-CH2-CH(X")-CH2-X' (where X" is hydroxyl and X' is an esterified hydroxy where X" given an epoxy group) with an amine R1-NH2 or a condensation product wiht an aldehyde or ketone. Cpds. are used esp. for coronary diseases or a general circulation improver.
Description
Verfahren zur Herstellung von neuen Phenoxyderivaten acyclischer gesättigter Hydroxylamine
Gegenstand der Erfindung ist ein Verfahren zur Herstellung von 1-(sek. - Amino)-2-hydroxy-3-(aryloxy)propanen der Formel
EMI1.1
worin alk einen Alkylenrest und R einen ungesättigten aliphatischen Kohlenwasserstoffrest darstellt, R1 einen aliphatischen Kohlenwasserstoffrest mit bis zu 15 Kohlenstoffatomen, der auch durch Sauerstoff-, Schwefel- oder Stickstoffatome unterbrochen sein kann und/oder durch Hydroxygruppen substituiert sein kann, einen cycloaliphatischen oder cycloaliphatisch-aliphatischen Kohlenwasserstoffrest mit bis zu 15 Kohlenstoffatomen, oder einen araliphatischen Kohlenwasserstoffrest mit bis zu 15 Kohlenstoffatomen, der insbesondere im aromatischen Kern, z.
B. wie weiter unten ausgeführt, substituiert sein kann, darstellt, und worin Ph einen gegebenenfalls substituierten 1,4-Phenylenrest darstellt, und der Salze dieser Verbindungen.
Der Alkylenrest alk ist insbesondere ein Niederalkylenrest mit 1-3 C-Atomen, insbesondere Methylen.
Der Rest R ist vor allem ein in beliebiger Stellung verbundener Propenyl- oder gerader oder verzweigter Butenyl-, Pentenyl- oder Hexenylrest oder ein entsprechender Rest mit Dreifachbindung; in erster Linie ist R der Vinylrest.
Vorzugsweise ist der Rest R-alk- der Allyl-, Methallyloder Propargylrest.
Als aliphatische Kohlenwasserstoffreste R1 kommen vor allem niedere gesättigte oder ungesättigte aliphatische Kohlenwasserstoffreste in Frage, vor allem niedere Alkylreste.
Bevorzugt sind dabei niedere gerade oder besonders verzweigte Alkylreste mit bis zu 5 Kohlenstoffatomen, wie Methyl, Äthyl, vor allem aber Isobutyl, 2-Methylbutyl, 3 Methyl-butyl und ganz besonders sekundäre oder tertiäre Alkylreste dieser Art, wie z. B. sek.-Butyl, Pentyl-(2), Pentyl-(3), 1,1-Dimethyl-propyl, tert.-Butyl und vor allem Isopropyl. Als niedere ungesättigte aliphatische Kohlenwasserstoffreste sind vor allem diejenigen der oben genannten Formel R-alk- zu erwähnen.
Durch Sauerstoff-, Schwefel- oder Stickstoffatome unterbrochene bzw. durch Hydroxylgruppen substituierte aliphatische Kohlenwasserstoffreste sind vor allem niedere Oxaalkylreste, vor allem solche, die sich von den genannten bevorzugten Alkylresten ableiten, z. B. Alkoxy-äthyl- oder -propylreste, oder Hydroxyalkylreste, wie ss-Hydroxyäthyloder ss- oder y-Hydroxypropylreste.
Als cycloaliphatische bzw. cycloaliphatisch-aliphatische Reste sind vor allem gesättigte oder ungesättigte Cycloalkyloder Cycloalkyl-niederalkylreste zu erwähnen, wie vor allem Cyclopropyl-, Cyclobutyl-, Cyclopentyl-, Cyclohexyl- oder Cycloheptylreste, sowie diese Reste tragende Methyl-, Äthyloder Propylreste, sowie solche Reste, die an geeigneter Stelle des Ringes oder einer Alkylenkette eine Doppelbindung aufweisen, sowie niedere Alkyl-, z. B. Methyl- oder Äthyl Substitutionsprodukte dieser Gruppen, oder solche Gruppen, deren Ringe eine Endobindung oder eine Endoalkylengruppe enthalten.
Araliphatische Kohlenwasserstoffreste sind insbesondere Aryl-niederalkylreste, wie vor allem Phenyl-niederalkylreste, worin der Niederalkylrest 1-3 Kohlenstoffatome aufweist, insbesondere Benzyl-, 1- oder 2-Phenyläthyl- oder 2- oder 3-Phenyl-propyl- oder 3-Phenyl-propyl-(2)-reste. In diesen araliphatischen Kohlenwasserstoffresten können vor allem die Arylreste ein-, zwei- oder mehrfach substituiert sein, z. B.
durch niedere Alkylgruppen, wie Methyl oder Äthyl, niedere Alkoxygruppen, wie Methoxy-, Äthoxy- oder Methylendioxygruppen, Halogenatome, wie Fluor-, Brom- oder insbesondere Chloratome, und/oder Trifluormethylgruppen.
Der 1,4-Phenylenrest Ph kann ebenfalls substituiert sein, z. B. durch niedere Alkylgruppen, wie Methyl oder Äthyl, niedere Alkoxygruppen, wie Methoxy-, Äthoxy- oder Methylendioxygruppen, Halogenatome, wie Fluor-, Bromoder insbesondere Chloratome, Trifluoromethylgruppen, Nitrogruppen, Aminogruppen, Acylaminogruppen, wie Niederalkanoylaminogruppen, z. B. Acetylaminogruppen, Gruppen der oben angegebenen Formel R-alk-O-, Phenyl-, Phenoxy-, Alkyloxyalkyl-, z. B. die genannten, Phenylalkoxy Cyan-, Cyan-alkyl-, Carboxy-, Carboxy-alkyl-, Mercapto-, Alkylmercapto-, Alkenyl-, Alkinyl-, Alkanoyl-, Benzoyl-, Phenylalkanoyl- oder Phenylsulfonylgruppen. Bevorzugt ist jedoch dieser Rest unsubstituiert.
Die neuen Verbindungen besitzen wertvolle pharmakologische Eigenschaften. So hemmen sie, wie sich im Dosisbereich von 0,01-30 mg/kg i.v. an der mit Dial narkotisierten Katze nach Isoproterenolgabe zeigen lässt, die cardi alenss-Rezeptoren, und zwar bevorzugt vor den vaskulären und bronchialen ss-Rezeptoren, und zeigen in einer Konzen tration von 1 1x10-8 x 104 bis 1 x 104 g/ml am isolierten Kanin- chenherzen nach Isoproterenolgabe ebenfalls einess-blockierende Wirkung. Ferner hemmen sie, wie sich in einer Dosierung von 0,03-30 mg/kg i.v. am Blutdruck der Katze zeigen lässt, die Kreislaufreflexe (CSR). Die neuen Verbindungen können daher als ss-Blocker und Antihypertensoren medikamentös bei Herz- und Kreislauferkrankungen oder psychosomatischen Symptomen dieser Art verwendet werden.
Besonders wertvoll sind die Verbindungen der Formel
EMI2.1
worin R und alk die oben gegebene Bedeutung haben und R3 einen aliphatischen Kohlenwasserstoffrest mit bis zu 15 Kohlenstoffatomen, vor allem einen niederen Alkylrest mit bis zu 5 Kohlenstoffatomen, besonders einen verzweigten niederen Alkylrest dieser Art, und in erster Linie einen sekundären oder tertiären Alkylrest mit höchstens 5 Kohlenstoffatomen, und speziell den tert.-Butyl- oder besser den Isopropylrest darstellt.
Aus dieser Gruppe ragen in bezug auf ihre Wirkungen diejenigen Verbindungen heraus, in denen der Rest R-alkder Allyl-, Methallyl- oder Propargylrest ist.
Eine in Anbetracht ihrer Wirkung besonders bevorzugte Verbindung ist das 1-Isopropylamino-2-hydroxy-3-(pallyloxy-phenoxy)-propan der Formel
EMI2.2
Das erfindungsgemässe Verfahren zur Herstellung der neuen Verbindungen ist dadurch gekennzeichnet, dass man in einem 1-(R1-Amino)-2-hydroxy-propan, das in 3-Stellung den Rest der Formel
R - alk - 0 - Ph - 0 worin R, alk, Ph und R1 die angegebenen Bedeutungen haben, trägt und das am Stickstoffatom einen durch Hydrolyse abspaltbaren Rest aufweist, oder in einem Salz davon, diesen durch Hydrolyse abspaltet. Solche Reste sind z. B.
Acylreste, insbesondere solche von Carbonsäuren, wie Oxycarbonylreste, wie der Benzyloxycarbonylrest oder der Trichlor-äthoxycarbonylrest, oder der tert.-Butoxycarbonylrest, oder Acylreste von aliphatischen Carbonsäuren, wie niedere Alkanoylreste, z. B. der Acetylrest.
Die Hydrolyse wird in üblicher Weise durchgeführt, beispielsweise in Gegenwart basischer Mittel, wie Alkalihydroxyden, oder vorzugsweise in Gegenwart von sauren Mitteln, wie verdünnten Säuren, z. B. Schwefelsäure oder Halogenwasserstoffsäure, z. B. Salzsäure.
Je nach den Verfahrensbedingungen und Ausgangsstoffen erhält man die Endstoffe in freier Form oder in der ebenfalls in der Erfindung inbegriffenen Form ihrer Salze. Die Salze der Endstoffe können in an sich bekannter Weise, z. B.
mit Alkalien oder Ionenaustauschern in die freie Base übergeführt werden. Von der letzteren lassen sich durch Umsetzung mit organischen oder anorganischen Säuren, insbesondere solchen, die zur Bildung von therapeutisch verwendbaren Salzen geeignet sind, Salze gewinnen. Als solche Säuren seien beispielsweise genannt: Halogenwasserstoffsäuren, Schwefelsäuren, Phosphorsäuren, Salpetersäure, Perchlorsäure, aliphatische, alicyclische, aromatische oder heterocyclische Carbon- oder Sulfonsäuren, wie Ameisen-, Essig-, Propion-, Bernstein-, Glykol-, Milch-, Äpfel-, Wein-, Zitronen-, Ascorbin-, Malein-, Hydroxymalein-, oder Brenztraubensäure; Phenylessig-, Benzoe-, p-Aminobenzoe-, Anthranil-, p-Hydroxybenzoe-, Salicyl- oder p-Aminosalicylsäure, Embonsäure, Methansulfon-, Äthansulfon-, Hydroxy äthansulfon-, Äthylensulfonsäure;
Halogenbenzolsulfon-, Toluolsulfon-, Naphthalinsulfonsäure oder Sulfanilsäure; Methionin, Tryptophan, Lysin oder Arginin.
Diese oder andere Salze der neuen Verbindungen, wie z. B. die Pikrate, können auch zur Reinigung der erhaltenen freien Base dienen, indem man die freien Basen in Salze überführt, diese abtrennt und aus den Salzen wiederum die Basen freimacht. Infolge der engen Beziehungen zwischen den neuen Verbindungen in freier Form und in Form ihrer Salze sind im vorausgegangenen und nachfolgend unter der freien Base sinn- und zweckmässig gegebenenfalls auch die entsprechenden Salze zu verstehen.
Die Erfindung betrifft auch diejenigen Ausführungsformen des Verfahrens, bei denen die Reaktionskomponenten gegebenenfalls in Form von Racematen, optischen Antipoden, Isomerengemischen und/oder Salzen vorliegen.
Die neuen Verbindungen können je nach Wahl der Ausgangsstoffe und Arbeitsweisen als optische Antipoden oder Racemate, oder, sofern sie mindestens zwei asymmetrische Kohlenstoffatome enthalten, auch als Isomerengemische (Racematgemische) vorliegen.
Gegebenenfalls erhaltene Isomerengemische (Racematgemische) können auf Grund der physikalisch-chemischen Unterschiede der Bestandteile in bekannter Weise in die beiden stereoisomeren (diastereomeren) reinen Racemate aufgetrennt werden, beispielsweise durch Chromatographie und/oder fraktionierte Kristallisation.
Erhaltene Racemate lassen sich nach bekannten Methoden in die Antipoden zerlegen, beispielsweise durch Umkristallisation aus einem optisch aktiven Lösungsmittel, mit Hilfe von Mikroorganismen oder durch Umsetzen mit einer, mit der racemischen Verbindung Salze bildenden optisch aktiven Säure und Trennung der auf diese Weise erhaltenen Salze, z. B. auf Grund ihrer verschiedenen Löslichkeiten in die Diastereomeren, aus denen die Antipoden durch Einwirkung geeigneter Mittel freigesetzt werden können. Besonders gebräuchliche optisch aktive Säuren sind z. B. die Dund L-Formen von Weinsäure, Di-o-Toluylweinsäure, Äpfelsäure, Mandelsäure, Camphersulfonsäure oder Chinasäure.
Vorteilhaft isoliert man den wirksameren der beiden Antipoden.
Zweckmässig verwendet man für die Durchführung der erfindungsgemässen Reaktionen solche Ausgangsstoffe, die zu den eingangs besonders erwähnten Gruppen von Endstoffen und besonders zu den speziell beschriebenen oder hervorgehobenen Endstoffen führen.
Die Ausgangsstoffe sind bekannt oder können, falls sie neu sind, nach an sich bekannten Methoden erhalten werden.
Verbindungen, die am Stickstoffatom einen durch Hydrolyse abspaltbaren Rest aufweisen, erhält man z. B. durch Kondensation einer Verbindung der Formel
EMI3.1
mit einer Verbindung der Formel Y11 (XVIII) worin Ph, R und alk die oben gegebenen Bedeutungen besitzen, und bei der Kondensation von Verbindungen XVI und XVIII X2 für Wasserstoff oder einen durch Hydrolyse abspaltbaren Rest und einer der Reste X, und Y1 für eine reaktionsfähig veresterte Hydroxylgruppe steht und der andere eine Aminogruppe bedeutet, die durch einen abspaltbaren Rest substituiert ist, und bei der Kondensation von Verbindungen XVII und XVIII Y1 eine durch einen abspaltbaren Rest substituierte Aminogruppe bedeutet, und wobei R1 die oben gegebenen Bedeutungen hat, und eine gegebenenfalls vorhandene durch den abspaltbaren Rest substituierte Hydroxylgruppe selektiv, z.
B. durch milde basische Hydrolyse, freisetzt.
Ferner sind diese am Stickstoff substituierten Verbindungen auch dadurch erhältlich, dass man ein p-(R-alk-O) Phenol, worin R und alk die oben gegebenen Bedeutungen haben, oder ein Salz davon mit einer Verbindung der Formel
EMI3.2
umsetzt, worin X' eine reaktionsfähig veresterte Hydroxylgruppe und von den Resten X2 und X'2 mindestens X2 ein durch Hydrolyse abspaltbarer Rest ist und der andere gegebenenfalls für Wasserstoff steht, und eine gegebenenfalls vorhandene, durch den abspaltbaren Rest substituierte Hydroxylgruppe selektiv, z. B. durch milde basische Hydrolyse, freisetzt.
Eine dritte Möglichkeit, die erwähnten, am Stickstoffatom substituierten Verbindungen zu erhalten, besteht darin, dass man in Verbindungen der Formel
EMI3.3
worin R und alk die oben gegebenen Bedeutungen besitzen und jeder der Reste X2 und X'2 für Wasserstoff steht, den abspaltbaren Rest in üblicher Weise einführt, z. B. durch Acylierung.
Die neuen Verbindungen können z. B. in Form pharmazeutischer Präparate Verwendung finden, welche sie in freier Form oder in Form ihrer nichttoxischen Salze in Mischung mit einem z. B. für die enterale oder parenterale Applikation geeigneten pharmazeutischen, organischen oder anorganischen, festen oder flüssigen Trägermaterial enthalten.
Beispiel 1
10,0 g 1-(N-Acetyl-isopropylamino)-2-hydroxy-3-(pallyloxy-phenoxy)-propan werden in 100 ml Äthanol gelöst. Nach Zugabe von 25 ml 5n Salzsäure kocht man 3 Stunden unter Rückfluss und dampft anschliessend im Vakuum ein. Der Rückstand wird in Wasser gelöst und durch Zugabe von 2n Natronlauge alkalisch gestellt. Es kristallisiert das 1 -(Isopropylamino)-2-hydroxy-3 -(p -allyloxy-phenoxy) - propan der Formel
EMI3.4
aus, das nach Umkristallisation aus Hexan bei 77-79 schmilzt. Das Hydrochlorid schmilzt bei 123-124".
Beispiel 2
In analoger Weise wie im Beispiel 1 beschrieben, kann man die folgenden Verbindungen erhalten: a) 1-Isopropylamino-2-hydroxy-3-(p-metallyloxyphenoxy)-propan und sein Hydrochlorid; b) 1 Isopropylamino-2-hydroxy-3-(p-propargyloxy- phenoxy)-propan-cyclohexylsulfamat, F 112-113"; c) 1-(tert. -Butylamino) -2-hydroxy-3 -(p- allyloxy- phenoxy)-propan-cyclohexylsulfamat, F. 127-128 ; und d) 1-Cyclopropylamino-2-hydroxy-3-(p-allyloxy- phenoxy)-propan, F. 6869".
Process for the preparation of new phenoxy derivatives of acyclic saturated hydroxylamines
The invention relates to a process for the preparation of 1- (sec - amino) -2-hydroxy-3- (aryloxy) propanes of the formula
EMI1.1
wherein alk is an alkylene radical and R is an unsaturated aliphatic hydrocarbon radical, R1 is an aliphatic hydrocarbon radical with up to 15 carbon atoms, which can also be interrupted by oxygen, sulfur or nitrogen atoms and / or can be substituted by hydroxyl groups, a cycloaliphatic or cycloaliphatic-aliphatic Hydrocarbon radical with up to 15 carbon atoms, or an araliphatic hydrocarbon radical with up to 15 carbon atoms, which is particularly in the aromatic nucleus, e.g.
B. as detailed below, may be substituted, and in which Ph is an optionally substituted 1,4-phenylene radical, and the salts of these compounds.
The alkylene radical alk is in particular a lower alkylene radical with 1-3 carbon atoms, in particular methylene.
The radical R is above all a propenyl radical or straight or branched butenyl, pentenyl or hexenyl radical connected in any position or a corresponding radical with a triple bond; R is primarily the vinyl radical.
The radical R-alk- is preferably the allyl, methallyl or propargyl radical.
Particularly suitable aliphatic hydrocarbon radicals R1 are lower saturated or unsaturated aliphatic hydrocarbon radicals, especially lower alkyl radicals.
Lower straight or particularly branched alkyl radicals with up to 5 carbon atoms, such as methyl, ethyl, but especially isobutyl, 2-methylbutyl, 3-methyl-butyl and very particularly secondary or tertiary alkyl radicals of this type, such as. B. sec-butyl, pentyl (2), pentyl (3), 1,1-dimethyl-propyl, tert-butyl and especially isopropyl. As lower unsaturated aliphatic hydrocarbon radicals, those of the above formula R-alk- are to be mentioned in particular.
Aliphatic hydrocarbon radicals interrupted by oxygen, sulfur or nitrogen atoms or substituted by hydroxyl groups are primarily lower oxaalkyl radicals, especially those which are derived from the preferred alkyl radicals mentioned, e.g. B. alkoxy-ethyl or -propyl radicals, or hydroxyalkyl radicals such as ß-hydroxyethyl or ß-or γ-hydroxypropyl radicals.
As cycloaliphatic or cycloaliphatic-aliphatic radicals, there are above all saturated or unsaturated cycloalkyl or cycloalkyl-lower alkyl radicals, such as, in particular, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl radicals, and also methyl, ethyl or propyl radicals bearing these radicals Radicals which have a double bond at a suitable point on the ring or an alkylene chain, as well as lower alkyl, e.g. B. methyl or ethyl substitution products of these groups, or those groups whose rings contain an endo bond or an endoalkylene group.
Araliphatic hydrocarbon radicals are in particular aryl-lower alkyl radicals, such as above all phenyl-lower alkyl radicals, in which the lower alkyl radical has 1-3 carbon atoms, especially benzyl, 1- or 2-phenylethyl or 2- or 3-phenyl-propyl or 3-phenyl propyl (2) radicals. In these araliphatic hydrocarbon radicals, the aryl radicals in particular can be substituted one, two or more times, e.g. B.
by lower alkyl groups such as methyl or ethyl, lower alkoxy groups such as methoxy, ethoxy or methylenedioxy groups, halogen atoms such as fluorine, bromine or, in particular, chlorine atoms, and / or trifluoromethyl groups.
The 1,4-phenylene radical Ph can also be substituted, e.g. B. by lower alkyl groups such as methyl or ethyl, lower alkoxy groups such as methoxy, ethoxy or methylenedioxy groups, halogen atoms such as fluorine, bromine or especially chlorine atoms, trifluoromethyl groups, nitro groups, amino groups, acylamino groups such as lower alkanoylamino groups, e.g. B. acetylamino groups, groups of the above formula R-alk-O-, phenyl, phenoxy, alkyloxyalkyl, z. B. the said, phenylalkoxy cyano, cyano-alkyl, carboxy, carboxy-alkyl, mercapto, alkylmercapto, alkenyl, alkynyl, alkanoyl, benzoyl, phenylalkanoyl or phenylsulfonyl groups. However, this radical is preferably unsubstituted.
The new compounds have valuable pharmacological properties. So they inhibit, as in the dose range of 0.01-30 mg / kg i.v. on the cat anesthetized with Dial after isoproterenol administration shows the cardi alenss receptors, preferably before the vascular and bronchial ss receptors, and shows in a concentration of 1 1x10-8 x 104 to 1 x 104 g / ml am isolated rabbit hearts also had a blocking effect after isoproterenol administration. They also inhibit, as shown in a dosage of 0.03-30 mg / kg i.v. the blood pressure of the cat shows the circulatory reflexes (CSR). The new compounds can therefore be used medicinally as SS blockers and antihypertensors for cardiovascular diseases or psychosomatic symptoms of this type.
The compounds of the formula are particularly valuable
EMI2.1
wherein R and alk have the meaning given above and R3 is an aliphatic hydrocarbon radical with up to 15 carbon atoms, especially a lower alkyl radical with up to 5 carbon atoms, especially a branched lower alkyl radical of this type, and primarily a secondary or tertiary alkyl radical with at most 5 carbon atoms, and especially the tert-butyl or better the isopropyl radical.
Out of this group, those compounds in which the radical R-alk is the allyl, methallyl or propargyl radical stand out with regard to their effects.
A compound which is particularly preferred in view of its effect is 1-isopropylamino-2-hydroxy-3- (pallyloxyphenoxy) propane of the formula
EMI2.2
The process according to the invention for the preparation of the new compounds is characterized in that in a 1- (R1-amino) -2-hydroxy-propane which is in the 3-position the remainder of the formula
R - alk - 0 - Ph - 0 in which R, alk, Ph and R1 have the meanings given, and which has a radical which can be split off by hydrolysis on the nitrogen atom, or in a salt thereof splits it off by hydrolysis. Such residues are e.g. B.
Acyl radicals, especially those of carboxylic acids, such as oxycarbonyl radicals, such as the benzyloxycarbonyl radical or the trichloro-ethoxycarbonyl radical, or the tert-butoxycarbonyl radical, or acyl radicals of aliphatic carboxylic acids, such as lower alkanoyl radicals, e.g. B. the acetyl radical.
The hydrolysis is carried out in a customary manner, for example in the presence of basic agents such as alkali metal hydroxides, or preferably in the presence of acidic agents such as dilute acids, e.g. B. sulfuric acid or hydrohalic acid, e.g. B. hydrochloric acid.
Depending on the process conditions and starting materials, the end products are obtained in free form or in the form of their salts, which is also included in the invention. The salts of the end products can in a conventional manner, for. B.
be converted into the free base with alkalis or ion exchangers. Salts can be obtained from the latter by reaction with organic or inorganic acids, in particular those which are suitable for the formation of therapeutically useful salts. Examples of such acids are: hydrohalic acids, sulfuric acids, phosphoric acids, nitric acid, perchloric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic or sulfonic acids, such as formic, acetic, propionic, succinic, glycolic, lactic, apple , Tartaric, citric, ascorbic, maleic, hydroxymaleic, or pyruvic acid; Phenylacetic, benzoic, p-aminobenzoic, anthranil, p-hydroxybenzoic, salicylic or p-aminosalicylic acid, emboxylic acid, methanesulphonic, ethanesulphonic, hydroxyethanesulphonic, ethylene sulphonic acid;
Halobenzenesulfonic, toluenesulfonic, naphthalenesulfonic acid or sulfanilic acid; Methionine, tryptophan, lysine or arginine.
These or other salts of the new compounds, such as. B. the picrates can also be used to purify the free base obtained by converting the free bases into salts, separating them and in turn frees the bases from the salts. As a result of the close relationships between the new compounds in the free form and in the form of their salts, in the preceding and in the following the free base is to be understood appropriately and appropriately, if appropriate, also to be the corresponding salts.
The invention also relates to those embodiments of the process in which the reaction components are optionally present in the form of racemates, optical antipodes, isomer mixtures and / or salts.
Depending on the choice of starting materials and working methods, the new compounds can be present as optical antipodes or racemates or, provided they contain at least two asymmetric carbon atoms, also as isomer mixtures (racemic mixtures).
Any isomer mixtures (mixtures of racemates) obtained can be separated into the two stereoisomeric (diastereomeric) pure racemates in a known manner on the basis of the physico-chemical differences between the constituents, for example by chromatography and / or fractional crystallization.
Racemates obtained can be broken down into the antipodes by known methods, for example by recrystallization from an optically active solvent, with the aid of microorganisms or by reaction with an optically active acid which forms salts with the racemic compound and separation of the salts obtained in this way, e.g. . B. due to their different solubilities in the diastereomers, from which the antipodes can be released by the action of suitable agents. Optically active acids commonly used are e.g. B. the D and L forms of tartaric acid, di-o-toluyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid or quinic acid.
It is advantageous to isolate the more effective of the two antipodes.
For carrying out the reactions according to the invention, it is expedient to use those starting materials which lead to the groups of end products particularly mentioned at the beginning and especially to the end products specifically described or emphasized.
The starting materials are known or, if they are new, can be obtained by methods known per se.
Compounds which have a residue that can be split off by hydrolysis on the nitrogen atom are obtained, for. B. by condensation of a compound of the formula
EMI3.1
with a compound of the formula Y11 (XVIII) in which Ph, R and alk have the meanings given above, and in the condensation of compounds XVI and XVIII X2 for hydrogen or a radical which can be split off by hydrolysis and one of the radicals X and Y1 for a reactive esterified hydroxyl group and the other is an amino group which is substituted by a removable radical, and in the condensation of compounds XVII and XVIII Y1 is an amino group substituted by a removable radical, and where R1 has the meanings given above, and an optionally present by the removable radical substituted hydroxyl group selectively, z.
B. by mild basic hydrolysis is released.
Furthermore, these nitrogen-substituted compounds can also be obtained by mixing a p- (R-alk-O) phenol, in which R and alk have the meanings given above, or a salt thereof with a compound of the formula
EMI3.2
converts, in which X 'is a reactive esterified hydroxyl group and of the radicals X2 and X'2 at least X2 is a radical which can be split off by hydrolysis and the other is optionally hydrogen, and an optionally present, substituted by the split-off radical hydroxyl group selectively, e.g. B. by mild basic hydrolysis is released.
A third possibility of obtaining the compounds mentioned, substituted on the nitrogen atom, consists in using compounds of the formula
EMI3.3
wherein R and alk have the meanings given above and each of the radicals X2 and X'2 is hydrogen, introduces the removable radical in the usual manner, e.g. B. by acylation.
The new connections can e.g. B. in the form of pharmaceutical preparations are used, which they in free form or in the form of their non-toxic salts mixed with a z. B. contain pharmaceutical, organic or inorganic, solid or liquid carrier material suitable for enteral or parenteral administration.
example 1
10.0 g of 1- (N-acetyl-isopropylamino) -2-hydroxy-3- (pallyloxyphenoxy) propane are dissolved in 100 ml of ethanol. After adding 25 ml of 5N hydrochloric acid, the mixture is refluxed for 3 hours and then evaporated in vacuo. The residue is dissolved in water and made alkaline by adding 2N sodium hydroxide solution. The 1 - (isopropylamino) -2-hydroxy-3 - (p -allyloxy-phenoxy) -propane of the formula crystallizes
EMI3.4
which, after recrystallization from hexane, melts at 77-79. The hydrochloride melts at 123-124 ".
Example 2
In a manner analogous to that described in Example 1, the following compounds can be obtained: a) 1-isopropylamino-2-hydroxy-3- (p-metallyloxyphenoxy) propane and its hydrochloride; b) 1 isopropylamino-2-hydroxy-3- (p-propargyloxyphenoxy) -propane-cyclohexylsulfamate, F 112-113 "; c) 1- (tert-butylamino) -2-hydroxy-3 - (p-allyloxy - phenoxy) propane cyclohexylsulfamate, F. 127-128; and d) 1-Cyclopropylamino-2-hydroxy-3- (p-allyloxyphenoxy) propane, F. 6869 ".
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1511271A CH529723A (en) | 1969-04-03 | 1969-04-03 | Unsatd. amine(s), tranquillisers and vasodilators |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH146971A CH529722A (en) | 1969-04-03 | 1969-04-03 | Unsatd. amine(s), tranquillisers and vasodilators |
| CH519069A CH529721A (en) | 1969-04-03 | 1969-04-03 | Unsatd. amine(s), tranquillisers and vasodilators |
| CH1511271A CH529723A (en) | 1969-04-03 | 1969-04-03 | Unsatd. amine(s), tranquillisers and vasodilators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH529723A true CH529723A (en) | 1972-10-31 |
Family
ID=25687741
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1511271A CH529723A (en) | 1969-04-03 | 1969-04-03 | Unsatd. amine(s), tranquillisers and vasodilators |
| CH1511171A CH527795A (en) | 1969-04-03 | 1969-04-03 | Unsatd. amine(s), tranquillisers and vasodilators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1511171A CH527795A (en) | 1969-04-03 | 1969-04-03 | Unsatd. amine(s), tranquillisers and vasodilators |
Country Status (1)
| Country | Link |
|---|---|
| CH (2) | CH529723A (en) |
-
1969
- 1969-04-03 CH CH1511271A patent/CH529723A/en not_active IP Right Cessation
- 1969-04-03 CH CH1511171A patent/CH527795A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH527795A (en) | 1972-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3241399A1 (en) | OPTICALLY ACTIVE OR RACEMIC PROSTAGLAND DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM | |
| EP0048218A1 (en) | N-oxide of N-oxacyclyl-alkyl piperidines, process for their preparation, pharmaceutical compositions containing these compounds as well as their therapeutical use | |
| DE2046043A1 (en) | Method for splitting DL 5 square bracket to 3 (tert butyl ammo) 2 hydroxypropoxy square bracket to 3,4 dihydro 1 (2H) naphthahnone into optical antipodes | |
| CH622491A5 (en) | Process for the preparation of novel hydroxypropylamines | |
| CH529723A (en) | Unsatd. amine(s), tranquillisers and vasodilators | |
| CH529722A (en) | Unsatd. amine(s), tranquillisers and vasodilators | |
| CH537361A (en) | Unsatd. amine(s), tranquillisers and vasodilators | |
| AT304471B (en) | Process for the preparation of new 1-sec.amino-2-hydroxy-3 - [(p-alkenyloxy- or p-alkinyloxy) -phenoxy] propanes and their acid addition salts | |
| AT305984B (en) | Process for the preparation of new 1-sec.amino-2-oxy-3- [p-alkenyloxy- or p-alkinyloxy) -phenoxy] -propanes and their acid addition salts | |
| AT304506B (en) | Process for the preparation of new anthracene compounds | |
| DE3323077A1 (en) | RACEMIC AND OPTICALLY ACTIVE EBURNANE OXIM ETHERS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| DE1227462B (en) | Process for the preparation of quinoline derivatives | |
| AT360018B (en) | METHOD FOR PRODUCING THE NEW 4- (7-BROM-5-METHOXY-2-BENZOFURANYL) PIPERIDINS AND ITS ACID ADDITION SALTS | |
| AT230875B (en) | Process for the preparation of the new (-) - 1- (4'-hydroxyphenyl) -2- (1 "-methyl-2" -phenoxyäthylamino) - ethanol and its acid addition salts | |
| DE2100422A1 (en) | New esters and methods of making them | |
| AT337677B (en) | METHOD FOR PREPARING NEW 9- (2-HYDROXY-3-AMINOPROPYL-9,10-DIHYDRO-9,10-ATHANOANTHRACENE | |
| DE1793799C2 (en) | 1 -Phenoxy ^ -hydroxyO-alkylaminopropanes, process for their preparation and pharmaceuticals containing these compounds | |
| CH465642A (en) | Process for the production of new amines | |
| CH523243A (en) | Antidepressant 2-subst pyrrolidine derivs | |
| DE2153803A1 (en) | Phenylalanine derivatives | |
| EP0080061A1 (en) | Cis-bicyclo(3.3.0)octane derivatives, medicines containing them and process for the preparation of these compounds and these medicines | |
| EP0014996A1 (en) | Heterocyclic spiro-amidines, their stereoisomers and optical isomers, methods for their preparation and medicaments containing them | |
| DE2530768A1 (en) | PHENOXYALKYLAMINE PYRIDYL ETHER AND THE METHOD FOR MANUFACTURING IT | |
| CH536273A (en) | 9-(alpha-methyl-phenethyl aminoalkyl)-9,10- - ethanoanthracenes | |
| DD202532A5 (en) | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 3-AMINO-1,2-PROPANDIOL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |